Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study

  1. Shiwani Mahajan
  2. Rajesh Srinivasan
  3. Carrie A. Redlich
  4. Sara K. Huston
  5. Kelly M. Anastasio
  6. Lisa Cashman
  7. Dorothy S. Massey
  8. Andrew Dugan
  9. Dan Witters
  10. Jenny Marlar
  11. Shu-Xia Li
  12. Zhenqiu Lin
  13. Domonique Hodge
  14. Manas Chattopadhyay
  15. Mark D. Adams
  16. Charles Lee
  17. Lokinendi V. Rao
  18. Chris Stewart
  19. Karthik Kuppusamy
  20. Albert I. Ko
  21. Harlan M. Krumholz

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.amjmed.2020.09.024
  2. ScreenIT

    SciScore for 10.1101/2020.08.04.20168203: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: The study was deemed not to be research by the Institutional Review Board at Yale University because of the public health surveillance activity exclusion and was approved by the Institutional Review Board at Gallup.
    Consent: Survey components: Individuals selected were provided study details, and informed consent was obtained from all participants by trained interviewers.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    We measured IgG SARS-CoV-2 antibodies using Ortho-Clinical Diagnostics Vitros anti-SARS-CoV-2 IgG test, which detects antibodies against the spike glycoprotein of the virus.
    anti-SARS-CoV-2 IgG
    suggested: None
    12 Additionally, given the concern about the accuracy of serology tests,13 we re-tested the negative samples from 5 high risk cities of Connecticut (i.e. Bridgeport, Hartford, New Haven, Stamford, and Waterbury) with the Abbott Architect SARS-CoV-2 IgG test that detects antibodies aimed at a different SARS-CoV-2 antigen (nucleocapsid protein).14 Finally, Quest Diagnostics provided results for all SARS-CoV-2 serology tests conducted throughout Connecticut in the same time period (i.e. June 10 and July 29, 2020) for comparison.
    antigen (nucleocapsid protein).14
    suggested: None
    Software and Algorithms
    SentencesResources
    All samples were processed at the Quest Diagnostics Marlborough Laboratory.
    Quest
    suggested: (QUEST, RRID:SCR_005210)
    12 Additionally, given the concern about the accuracy of serology tests,13 we re-tested the negative samples from 5 high risk cities of Connecticut (i.e. Bridgeport, Hartford, New Haven, Stamford, and Waterbury) with the Abbott Architect SARS-CoV-2 IgG test that detects antibodies aimed at a different SARS-CoV-2 antigen (nucleocapsid protein).14 Finally, Quest Diagnostics provided results for all SARS-CoV-2 serology tests conducted throughout Connecticut in the same time period (i.e. June 10 and July 29, 2020) for comparison.
    Abbott Architect
    suggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)
    All statistical analyses were performed using SPSS 24.0 (SPSS, Inc. Chicago, IL) and R version 4.0.2.
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.08.04.20168203v2 on medRxiv
  4. Version published to 10.1101/2020.08.04.20168203v1 on medRxiv